Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Net Income

Bottom-line profit after all expenses, interest, and taxes.

Bio-Rad Laboratories, Inc.NYSE: BIO

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $371.4M rose 16.9% year over year, ahead of the -30.3% change in trailing-twelve-month net income.

Context

  • Net income amounted to 29.4% of revenue in FY2025, down 42.4 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of $271.33M (-64.3%) for the fiscal year ending Dec 2026, a slowdown from the +141.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$371.4M+170.5% QoQ
Last fiscal yearDec 2025
$759.9M+141.2% YoY
LTMJun 2026
$222.4M-30.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.9%+117.5%+100.7 pp
1 year+141.2%-64.3%-205.5 pp
3-year CAGR—-24.8%—
5-year CAGR-11.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
759.9M USD
Year-over-year change
+141.2%
4-year CAGR
-35.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 net income of $222.4M is the 4th highest of the 11 companies compared; the peer median is -$14.83M.
  • Its year-over-year change of -30.3% is the 9th highest of 11, against a peer median of +26.4%.
  • Net income amounts to 8.6% of revenue for BIO, versus a peer median of 15.9%.
BIO Competitors Peer median
Net Income for BIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$7.08B +7.8%-1.0%15.0%
DHRDanaher CorporationLTM Sep 2026$4.33B +23.6%-20.6%16.9%
RVTYRevvity, Inc.LTM Jul 2026$237.55M -17.1%-24.8%8.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$222.4M -30.3%—8.6%
TECHBio-Techne CorporationLTM Sep 2026$171.97M +120.5%-13.9%14.0%
RGENRepligen CorporationLTM Jun 2026$41.54M +400.4%-35.9%5.3%
BRKRBruker CorporationLTM Jun 2026-$71.2M -189.4%—2.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$77.39M +60.3%—37.1%
LABStandard BioTools Inc.LTM Mar 2026-$94.08M +29.1%—109.1%
PACBPacific Biosciences of California, Inc.LTM Mar 2026-$128.58M +80.5%—80.3%
AZTAAzenta, Inc.LTM Sep 2026-$166.99M -212.8%—26.9%
Peer median (excluding BIO) -$14.83M+26.4%-20.6%15.9%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.92B2.8B2.67B2.57B2.58B
Cost of Revenue1.28B1.23B1.24B1.19B1.24B
Gross Profit1.64B1.57B1.43B1.38B1.34B
Gross Margin56.1%55.9%53.4%53.7%52.0%
Research & Development260.64M256.89M247.43M295.9M256.9M
Selling, General & Admin877.12M827.83M841.7M814M819.9M
Operating Expenses1.14B1.08B1.09B1.11B1.08B
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
EBITDA5.59B(4.53B)(654.8M)(2.14B)1.21B
EBITDA Margin191.2%-161.6%-24.5%-83.5%46.8%
Operating Income500.34M482.62M337.8M269M270.5M
Operating Margin17.1%17.2%12.6%10.5%10.5%
Interest Income18.9M58M100.9M82M95.5M
Interest Expense1.55M38.11M49.44M48.9M49M
Other Income / Expenses4.95B(5.19B)(1.19B)(2.61B)725M
Income Before Tax5.45B(4.7B)(850.1M)(2.34B)995.5M
Pre-Tax Margin186.4%-167.9%-31.8%-91.3%38.5%
Income Tax Expense1.19B(1.08B)(212.78M)(498.3M)235.6M
Net Income4.25B(3.63B)(637.32M)(1.84B)759.9M
Net Margin145.6%-129.5%-23.9%-71.9%29.4%
EPS (Basic)142.61(121.79)(21.82)(65.36)27.87
EPS (Diluted)140.83(121.79)(21.82)(65.36)27.87
Weighted Avg Shares29.83M29.79M29.21M28.21M27.26M
Weighted Avg Shares (Diluted)30.21M29.79M29.21M28.21M27.28M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.